Trial Profile
A Phase I, Open Label, Parallel Group, Single and Multiple Dose Study in Taiwanese Subjects Identified as CYP2C19 Poor Metabolizers or Extensive Metabolizers Receiving 20 Milligrams of Rosuvastatin Calcium.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors AstraZeneca
- 27 Feb 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 27 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2008 New trial record.